
|Videos|January 30, 2023
Combination Ruxolitinib and Selinexor for the Treatment of Naïve Myelofibrosis
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5




























